Committee Connection
  • JCO Exclusive: In Pediatric Phase I Trials, Hope Is Emphasized over Realism

    15 Sep 2014 04:05 PM

                        Key Points The study found that for every one “realistic” statement doctors made during informed consent conferences (ICCs), they made three hopeful statements indicating that the treatment could bring about positive outcomes, such as lengthening the life of the child. The study also found that in 68% of the ICCs, doctors failed to mention that parents... Read more

  • JCO Exclusive: Oncology Fellows Underestimate Their Workload—Which May Lead to Burnout

    08 Sep 2014 03:57 PM

                        Key Points   The study found that fellows underestimated the number of nights they would need to be on call, the number of hours they would need to devote to work tasks when at home, and the number of outpatients seen in clinic per week. The study also found that fatigue and quality of life improve once oncologists start practicing, but career... Read more

  • JCO Exclusive: Late Hospice Admission—Can It Be Predicted?

    02 Sep 2014 04:42 PM

                        Key Points Patients who were admitted to hospice in the last three days of life were significantly more likely to have a hematologic malignancy, to be male, married, and younger than age 65. These factors are outside of doctors’ influence and are, therefore, important to consider when designing quality assessment programs that would rate doctors by the... Read more

  • Risk of Diabetes Higher Among Survivors of Hodgkin Lymphoma

    25 Aug 2014 04:30 PM

                        Key Points This study found that 30 years after treatment for adolescent and adult Hodgkin lymphoma (HL), 8.3% of survivors had developed diabetes mellitus (DM), a significantly higher rate than in the general population. Overall, HL survivors had 2.6-fold increased risk of developing DM compared to the general population. Risk of DM escalated with dose;... Read more

  • ASCO Mourns Jesse L. Steinfeld, MD, Former Surgeon General, ASCO President

    18 Aug 2014 11:04 AM

       Photo courtesy of Virginia Common-wealth UniversityASCO and the cancer community mourn the loss of Jesse Leonard Steinfeld, MD, who died on August 5, 2014, at age 87 from complications of a stroke. Dr. Steinfeld was an ardent advocate of building public awareness of the dangers of tobacco and smoking, a former U.S Surgeon General, and Past President of ASCO. “I knew him to be a man committed to public health and absolutely dedicated... Read more

  • EGFR-Inhibitors and the JCO Study that Cleared the Way for FDA Approval

    11 Aug 2014 04:07 PM

                        Key Points This 2013 study showed that, among patients with EGFR mutation-positive metastatic lung adenocarcinoma, the tyrosine-kinase inhibitor (TKI), afatinib, was superior to the chemotherapy combination of cisplatin plus pemetrexed in terms of progression-free survival (PFS) and patient-reported outcomes (PRO). Patients who received afatinib had a... Read more

  • Statins May Reduce Death among Patients with Colorectal Cancer

    04 Aug 2014 04:22 PM

                        Key Points With a cohort of 7,657 patients, this U.K. study is the largest to date to investigate statin use after colorectal cancer diagnosis. Overall, researchers observed a 29 % reduction in colorectal cancer-related deaths among patients who used statins after diagnosis compared to those who did not use statins. Longer than one-year use of statins... Read more

  • The Rise and Fall of Erythropoiesis-Stimulating Agents: Medicare Reimbursement Is the Key

    28 Jul 2014 04:04 PM

                        Key Points Erythropoiesis-stimulating agents (ESAs) were quickly embraced by oncologists after their approval in the early 1990’s and 2000s. But soon after, data showed the drugs led to adverse events, leading the FDA to issue black box warnings. In addition, CMS issued a new coverage policy that limited ESA reimbursement except in cases of documented... Read more

  • A Continuing Commitment: A Look into the IDEA Program

    16 Jul 2014 01:44 PM

    Perspective from L. Michael Glodé, MD, FACP, FASCO, an IDEA Mentor     Dr. Maria Bourlon and Dr. L. Michael Glodé at a Conquer  Cancer Foundation eventI first heard about the International Development and Education Award (IDEA) program in an email from ASCO that asked for volunteers who were willing to host a fellow from abroad. I responded, listing my areas of interest, and I was gratified to be contacted by the... Read more

  • HPV is the Driving Force behind the Rise of Oropharyngeal Cancer

    14 Jul 2014 04:03 PM

                        Key Points First American study to show that from the 1980s through the 2000s, the proportion of tumors that carried HPV rose over time and that rise tightly paralleled the increase in rates of OPSCC. This observation led to the study’s conclusion: the increase in cases of oropharyngeal cancers in the United States since 1984 are caused by HPV infection.... Read more